Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01670084 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Oct 30, 2015 | clinicaltrials |
| NCT00578045 | UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies | withdrawn | Phase 1 | 0 | University of ArkansasOTHER | 1 | Oct 26, 2015 | clinicaltrials |
| NCT01263418 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Oct 12, 2015 | clinicaltrials |
| NCT00093678 | Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer | withdrawn | N/A | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT01180569 | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Sep 25, 2015 | clinicaltrials |
| NCT00003605 | Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00003663 | Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00004039 | Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma | withdrawn | Phase 2 | 0 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01490047 | Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas | withdrawn | Phase 1 | 0 | Ludwig Institute for Cancer ResearchOTHER | 1 | Jun 16, 2015 | clinicaltrials |
| NCT01271283 | Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01843998 | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | withdrawn | Phase 2 | 0 | Stefan Schieke MDOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00770419 | Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers | withdrawn | — | 0 | Rutgers, The State University of New JerseyOTHER | 0 | May 29, 2015 | clinicaltrials |
| NCT02150928 | An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase) | withdrawn | Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | May 13, 2015 | clinicaltrials |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | withdrawn | N/A | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | May 7, 2015 | clinicaltrials |
| NCT00498667 | The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma | withdrawn | — | 0 | Rambam Health Care CampusOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00024115 | BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT02082405 | Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Apr 24, 2015 | clinicaltrials |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | withdrawn | Phase 3 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 17, 2015 | clinicaltrials |
| NCT00503763 | Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma(PSMMSS) | withdrawn | Phase 2 | 0 | Meir Medical CenterOTHER | 0 | Apr 16, 2015 | clinicaltrials |
| NCT00242528 | Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. | withdrawn | Phase 4 | 0 | NovartisINDUSTRY | 0 | Apr 14, 2015 | clinicaltrials |
| NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib | withdrawn | Phase 2 | 0 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Apr 6, 2015 | clinicaltrials |
| NCT00210340 | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis | withdrawn | Phase 1 | 0 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 0 | Mar 30, 2015 | clinicaltrials |
| NCT00723658 | S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00833534 | Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 0 | Mar 6, 2015 | clinicaltrials |
| NCT00845104 | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 0 | Mar 6, 2015 | clinicaltrials |
| NCT01055301 | S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma(DMV) | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2015 | clinicaltrials |
| NCT01386398 | Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jan 21, 2015 | clinicaltrials |
| NCT02115035 | A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 1 | Aug 27, 2014 | clinicaltrials |
| NCT01688752 | Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia | withdrawn | — | 0 | University of MinnesotaOTHER | 0 | Aug 22, 2014 | clinicaltrials |
| NCT02095574 | A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma | withdrawn | Phase 1 | 0 | AbbVieINDUSTRY | 0 | Aug 13, 2014 | clinicaltrials |
| NCT00458744 | Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment | withdrawn | Phase 1 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 8, 2014 | clinicaltrials |
| NCT02114502 | Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 11, 2014 | clinicaltrials |
| NCT01969682 | A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 | withdrawn | Phase 1 | 0 | AbbVieINDUSTRY | 1 | May 26, 2014 | clinicaltrials |
| NCT00898612 | Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant | withdrawn | — | 0 | Mayo ClinicOTHER | 1 | Mar 10, 2014 | clinicaltrials |
| NCT00521261 | Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | withdrawn | Phase 1 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Mar 5, 2014 | clinicaltrials |
| NCT01251250 | Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jan 13, 2014 | clinicaltrials |
| NCT01854372 | Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement. | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Dec 10, 2013 | clinicaltrials |
| NCT00957320 | Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL) | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Dec 3, 2013 | clinicaltrials |
| NCT01355783 | A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma | withdrawn | Phase 3 | 0 | Eisai Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00457574 | Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas | withdrawn | Phase 1 | 0 | Gemin XINDUSTRY | 0 | Aug 28, 2013 | clinicaltrials |
| NCT00829205 | Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | withdrawn | Phase 1 / Phase 2 | 0 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01671813 | Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly | withdrawn | N/A | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Jul 25, 2013 | clinicaltrials |
| NCT01044004 | Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Jul 23, 2013 | clinicaltrials |
| NCT00872976 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2013 | clinicaltrials |
| NCT00003502 | Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003505 | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | OncotherapeuticsINDUSTRY | 1 | Jul 10, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Oct 30, 2015source: clinicaltrials